Catalent Cell and Gene Content

  1. The Journey Into Cell & Gene Therapy 8/13/2020

    Hear about our venture into the development and manufacturing of viral vector gene therapies and how we are overcoming challenges and maintaining our commitment to our partners.

  2. Radiance Label-Free Monitoring Of AAV Transfection In HEK293 Cells 7/13/2020

    Improve the characterization of cell-based AAV transfection and production, increase the efficiency and accuracy of both processes, and shorten development time.

  3. Are Real-Time Gene Therapy Test Results Possible?

    Along with the complexities of vaccine and viral-based gene therapy process development comes the need for analytical techniques that can help assess quality parameters, especially in real-time.

  4. Unprecedented Growth — And Challenges — In Gene Therapy

    The gene therapy clinical pipeline is in a high growth phase, with an influx of venture capital funding. There are also challenges: scalability, dosing, and the price of the final treatment.

  5. Manufacturing Strategies To Industrialize Autologous Cell Therapies

    While the first autologous cell therapy commercial products have shown tremendous clinical success, scaling out these therapies while considering individual patient processes is a new challenge.

  6. The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies

    The success of using viral vectors to deliver a molecular payload into a cell or replace defective genes with functional ones is an inflection point in the future of modern medicine.

  7. Technology Integrators In Cell And Gene Therapy: Powering Innovation

    Accelerated clinical trial timelines for advanced therapeutics are on the rise. With fast-track status designations, it is increasingly critical for innovators to have efficient and scalable production processes.

  8. Preparing For The Commercial Scale Production Of Cell Therapies

    In this review, we discuss a few attributes that should be considered when planning manufacturing at scale for your cell therapy.

  9. Integrated Solutions For Advanced Therapeutics

    Our development expertise across all gene therapy modalities (AAV, lentivirus, oncolytic virus, etc.) and proven clinical through commercial scale-up capabilities will provide full life cycle support of your life-saving therapeutic.

  10. Manufacturing Innovation Across New Modalities

    The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next scalability challenge.